Literature DB >> 2140413

(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist.

S E Hillver, L Björk, Y L Li, B Svensson, S Ross, N E Andén, U Hacksell.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140413     DOI: 10.1021/jm00168a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  5 in total

1.  5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram.

Authors:  L Arborelius; G G Nomikos; P Grillner; P Hertel; B B Höök; U Hacksell; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

2.  Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.

Authors:  Rui Xiong; Hitisha K Patel; Lauren M Gutgesell; Jiong Zhao; Loruhama Delgado-Rivera; Thao N D Pham; Huiping Zhao; Kathryn Carlson; Teresa Martin; John A Katzenellenbogen; Terry W Moore; Debra A Tonetti; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2015-12-30       Impact factor: 7.446

3.  The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum.

Authors:  G G Nomikos; L Arborelius; B B Höök; U Hacksell; T H Svensson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  The 5-HT1A receptor antagonist (S)-UH-301 blocks the qR)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat.

Authors:  L Arborelius; B B Höök; U Hacksell; T H Svensson
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons.

Authors:  L Arborelius; K Chergui; S Murase; G G Nomikos; B B Höök; G Chouvet; U Hacksell; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.